In a multi-year research alliance, the companies aim to combine Seagen’s antibody technology with compounds that can degrade cancer-driving proteins.Dive Brief:Seagen is committing $60 million to develop a new type of cancer drug, striking a multi-year alliance with biotechnology company Nurix that aims to combine their respective technologies.Per terms of the deal announced by Nurix […]
